GlassScriptPhysician profile
Frank Duncan Scott
NPI 1508804733
$4,018.41
in general payments reported to CMS, 2019-2025
12 companies · $607 in 2025
The $607 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $43.80 · 2022: $20.65 · 2023: $1,685 · 2024: $1,542 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,400 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,400 · Food and Beverage: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,400.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,400.00 |
| Food and Beverage | $1,033.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Outset Medical INC | $2,800.00 | 2023-2024 | |
| Ceribell, INC. | $278.45 | 2023-2025 | Pocket Eeg Device, Ceribell Rapid Response |
| Astellas Pharma US INC | $234.99 | 2023-2024 | Cresemba |
| Merck Sharp & Dohme LLC | $125.00 | 2025 | Zerbaxa |
| Teva Pharmaceuticals USA, INC. | $121.84 | 2025 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $115.15 | 2025 | Entyvio |
| Alpha Cognition USA, INC. | $98.88 | 2025 | Zunveyl |
| Amarin Pharma, INC. | $89.63 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $59.29 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $51.38 | 2019-2022 | |
| Lilly USA, LLC | $32.39 | 2020 | |
| Sanofi Pasteur INC. | $11.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.